T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.45B |
| 2 |
Pinterest
PINS
|
+$1.89B |
| 3 |
T-Mobile US
TMUS
|
+$1.89B |
| 4 |
Zoom
ZM
|
+$1.77B |
| 5 |
UiPath
PATH
|
+$1.71B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$3.66B |
| 2 |
Caterpillar
CAT
|
+$1.32B |
| 3 |
Netflix
NFLX
|
+$1.18B |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$1.15B |
| 5 |
Micron Technology
MU
|
+$1.07B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.62% |
| 2 | Healthcare | 16.07% |
| 3 | Consumer Discretionary | 15.29% |
| 4 | Communication Services | 13.46% |
| 5 | Financials | 12.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2351
Willdan Group
WLDN
$1.29B
| $540K | ﹤0.01% |
14,342
+2,464
| +21% | +$95.2K |
|
2352
Occidental Petroleum Corp Warrants
OXY.WS
$33.7B
| $539K | ﹤0.01% |
38,727
| – | – |
|
2353
Collegium Pharmaceutical
COLL
$913M
| $538K | ﹤0.01% |
22,747
-3,058
| -12% | -$70.6K |
|
2354
Scansource
SCSC
$1.06B
| $538K | ﹤0.01% |
19,131
+332
| +2% | +$9.88K |
|
|
TRUE
2355
DELISTED
TrueCar
TRUE
| $536K | ﹤0.01% |
94,919
-48,291
| -34% | -$243K |
|
2356
Univest Financial
UVSP
$1.19B
| $535K | ﹤0.01% |
20,273
+622
| +3% | +$17.5K |
|
2357
Vishay Precision Group
VPG
$908M
| $534K | ﹤0.01% |
15,686
+74
| +0.5% | +$2.46K |
|
2358
MannKind Corp
MNKD
$1.2B
| $532K | ﹤0.01% |
97,693
+5,986
| +7% | +$25.9K |
|
|
GOOD
2359
Gladstone Commercial Corp
GOOD
$641M
| $531K | ﹤0.01% |
23,554
-1,790
| -7% | -$38.3K |
|
2360
iShares Core S&P Small-Cap ETF
IJR
$113B
| $531K | ﹤0.01% |
4,703
| – | – |
|
2361
Atara Biotherapeutics
ATRA
$76.7M
| $529K | ﹤0.01% |
1,361
+195
| +17% | +$69.6K |
|
2362
Universal Electronics
UEIC
$66.6M
| $529K | ﹤0.01% |
10,907
+249
| +2% | +$12.9K |
|
2363
Talos Energy
TALO
$2.58B
| $528K | ﹤0.01% |
33,763
-8,710
| -21% | -$120K |
|
|
CAMP
2364
DELISTED
CalAmp Corp.
CAMP
| $527K | ﹤0.01% |
1,802
-964
| -35% | -$287K |
|
|
ZOM
2365
DELISTED
Zomedica Corp.
ZOM
| $527K | ﹤0.01% |
632,600
+244,800
| +63% | +$228K |
|
2366
BancFirst
BANF
$3.89B
| $524K | ﹤0.01% |
8,390
+234
| +3% | +$16.1K |
|
2367
Interparfums
IPAR
$3.7B
| $524K | ﹤0.01% |
7,275
+296
| +4% | +$21.8K |
|
2368
Invesco Mortgage Capital
IVR
$805M
| $524K | ﹤0.01% |
13,444
-5,079
| -27% | -$192K |
|
2369
Coherus Oncology
CHRS
$176M
| $523K | ﹤0.01% |
37,810
+1,284
| +4% | +$18.2K |
|
2370
Theravance Biopharma
TBPH
$878M
| $520K | ﹤0.01% |
35,837
-1,937
| -5% | -$36.4K |
|
2371
OceanFirst Financial
OCFC
$1.88B
| $518K | ﹤0.01% |
24,850
+951
| +4% | +$21.3K |
|
|
ZEUS
2372
DELISTED
Olympic Steel
ZEUS
| $517K | ﹤0.01% |
17,604
-2,034
| -10% | -$64.1K |
|
|
ZGNX
2373
DELISTED
Zogenix, Inc.
ZGNX
| $517K | ﹤0.01% |
29,896
-1,199
| -4% | -$22.1K |
|
2374
Canterbury Park Holding Corp
CPHC
$81.4M
| $516K | ﹤0.01% |
34,447
| – | – |
|
|
RVI
2375
DELISTED
Retail Value Inc. Common Shares
RVI
| $515K | ﹤0.01% |
258,209
+2,463
| +1% | +$4.38K |
|
Similar funds
T. Rowe Price Associates's Q2 2021 Portfolio in Review
As of Q2 2021, T. Rowe Price Associates held 3,000 positions worth $1.08T, up 8% from $999B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2021 filing shows 159 new, 1,164 increased, 1,499 reduced and 84 closed positions. Its largest new stake was UiPath: 23,377,090 shares worth $1.52B. The largest sale was Alibaba, an estimated $3.66B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2021 buy was UiPath: 23,377,090 shares worth $1.52B.
- T. Rowe Price Associates added most to Microsoft in Q2 2021, an estimated $3.45B increase.
- T. Rowe Price Associates's biggest Q2 2021 reduction was Alibaba, cutting an estimated $3.66B.
- T. Rowe Price Associates fully exited Pershing Square Tontine Holdings, Ltd. in Q2 2021, selling an estimated $145M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.08T portfolio in Q2 2021.
- T. Rowe Price Associates opened 159 new positions and closed 84 in Q2 2021.
- T. Rowe Price Associates's portfolio value rose 8% quarter-over-quarter to $1.08T.
Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.